News
31mon MSN
Bristol Myers Beats Earnings Expectations. It’s Still Optimistic About New Schizophrenia Drug.
Cobenfy is one of the key products Bristol is counting on to take up the slack as patents on three of its top-selling drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback